| Identification | Back Directory | [Name]
Ethanone, 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-1-[(2R)-2-methyl-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)-5-pyrimidinyl]-5-thiazolyl]-1-piperazinyl]- | [CAS]
1646267-59-5 | [Synonyms]
ACT-660602
Ethanone, 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-1-[(2R)-2-methyl-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)-5-pyrimidinyl]-5-thiazolyl]-1-piperazinyl]- | [Molecular Formula]
C20H20F6N8OS | [MOL File]
1646267-59-5.mol | [Molecular Weight]
534.48 |
| Chemical Properties | Back Directory | [Boiling point ]
611.0±65.0 °C(Predicted) | [density ]
1.60±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.59±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
ACT-660602 is a Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases. ACT-660602 led to significantly reduced recruitment of the CXCR3+ CD8+ T cell in the bronchoalveolar lavage compartment when administered orally at a dose of 30 mg/kg. |
|
|